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Francis Diabetes Center, 17 Doctors Park, Cape GirardeObjective: To present the challenges of undiagnosed pre-diabetes, diabetes and associated cardiovascular
disease.
Results: A substantial number of people with diabetes and pre-diabetes remain undiagnosed worldwide.
Without preventive measures, pre-diabetes progresses to overt diabetes at the rate of approximately 5%
per year. Both diabetes and pre-diabetes are associated with vascular complications.
Conclusion: Undiagnosed pre-diabetes and diabetes is a major health problem, and we recommend wide-
spread screening for diabetes. An international expert committee has recommended that HbA1c be used
for the diagnosis of diabetes. Further studies are needed before HbA1c can be used as a diagnostic test for
gestational diabetes.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.1. Introduction
The prevalence of diabetes and pre-diabetes has reached epi-
demic proportions. It is estimated that currently, approximately
7.8% of the US population or 23.6 million Americans have diabetes
[1]. Of these, 17.9 million people are diagnosed and 5.7 million
people have diabetes that has not been diagnosed. In addition,
there are an estimated 57 million people who have ‘‘pre-diabetes”
[1]. In 2005–2006, the crude prevalence of total diabetes in the US
among people agedP20 years was 12.9%, of which approximately
40% (of cases) were undiagnosed. In addition 29.5% had pre-diabe-
tes [2]. In the UK, the overall weighted prevalence of diabetes was
9.1% and 1.7% had undiagnosed diabetes. Of the cases of diabetes,
18.5% were undiagnosed [3]. It is projected that the global preva-
lence of diabetes will approximately double by the year 2030 [4].
Worldwide, the number of people with pre-diabetes (impaired glu-
cose tolerance) in the age group 20–79 was 308 million in 2007,
and is expected to increase to 418 million by the year 2025 [5].
Pre-diabetes, as diagnosed by impaired fasting glucose (IFG) or
impaired glucose tolerance (IGT), progresses to overt diabetes at
the rate of approximately 5% per year [6] unless some interven-
tions are introduced [7]. Diabetes is associated with an increasedellitus. Published by Elsevier Ltd.
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Orisk of microvascular (diabetic retinopathy, nephropathy, and neu-
ropathy) [8], as well as macrovascular complications such as myo-
cardial infarction, stroke or peripheral vascular disease [9]. The
majority of patients with type 2 diabetes mellitus die due to car-
diovascular complications [10]. Thus, a missed diagnosis of diabe-
tes amounts to a missed diagnosis of cardiovascular disease [11].2. Diagnosis of diabetes and pre-diabetes
Since both fasting and postprandial glucose levels in the popu-
lation are distributed in a unimodal fashion, the diagnosis of diabe-
tes and more recently pre-diabetes has been made by somewhat
arbitrary criteria. Prior to the criteria for diagnosis of diabetes pro-
mulgated by the National Diabetes Data Group [12], there was no
agreement about the levels of plasma glucose at which a diagnosis
of diabetes mellitus could be made. These criteria were revised in
1997 [13], and are still used widely to make a diagnosis of diabetes
mellitus. At that time, the glycemic threshold for making a diagno-
sis of diabetes was lowered from a fasting plasma glucose of 140
mg/dl to a plasma glucose level of 126 mg/dl. Also at that time,
pre-diabetes was deﬁned as either an impaired fasting glucose
(IFG), i.e., FPG 110–125 mg/dl, or impaired glucose tolerance
([IGT), i.e., 2 h post glucose load plasma glucose 140–199 mg/dl.
The criteria for impaired IFG were subsequently revised to FPG
100–125 mg/dl [14]. The reasons for this decision by the expert
committee were several, and are discussed in detail in their report
[14].pen access under CC BY-NC-ND license.
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It is well known that people with pre-diabetes have an in-
creased risk of progression to type 2 diabetes mellitus [6,15]. Sev-
eral studies have followed the progression of IFG and IGT to the
development of overt diabetes. An evaluation of these studies re-
veals that although there are some differences among studies, it
appears that IFG or IGT progresses to overt diabetes at the rate of
approximately 5% per year. The risk appears to be similar with iso-
lated IFG or IGT, and is highest for those who have combined IFG
and IGT [6].
A review of several studies of prevention of diabetes from pre-
diabetes revealed that with life style interventions the relative risk
reduction ranged from 28% to 67% while with the use of some
drugs the relative risk reduction was 26–60% [16]. A larger meta-
analysis to quantify the effectiveness of pharmacologic and life-
style interventions to prevent or delay type 2 diabetes in people
with IGT determined that the pooled hazard ratios were 0.51
(95% conﬁdence interval 0.44–0.60) for life style interventions vs.
standard advice, 0.70 (0.62–0.79) for oral diabetes drugs vs. con-
trols, 0.44 (0.28–0.69) for Orlistat vs. controls and 0.32 (0.03–
3.07) for herbal remedy Jiangtang recipe vs. standard advice. The
authors concluded that life style and pharmacologic interventions
reduce the rate of progression to type 2 diabetes in people with
IGT, and that the lifestyle interventions seem to be at least as effec-
tive as drug treatment [7]. It should be mentioned that at the pres-
ent time no drugs are approved by the Federal Drug Administration
in the USA for the treatment of pre-diabetes.
Although either IFG and/or IGT can be used to make a diagnosis
of pre-diabetes, their signiﬁcance in terms of progression of disease
and the cardiovascular complications may not be the same. For
example, a study from Mauritius [17] demonstrated that for pre-
dicting progression to type 2 diabetes, the sensitivity, speciﬁcity,
and positive predictive values were 26%, 94% and 29% for IFG and
50%, 84% and 24% for IGT, respectively. The authors concluded that
IGT had higher sensitivity over IFG for predicting progression to
type 2 diabetes [17].
Similarly in the Fungata study, it was observed that IGT was a
risk factor for cardiovascular disease, but IFG was not [18]. An
international workshop on impaired glucose tolerance and im-
paired fasting glycemia [6] concluded that: (i) in the majority of
populations studied, IGT is more prevalent than IFG, (ii) IFG is sub-
stantially more common amongst men, and IGT slightly more com-
mon amongst women, (iii) the prevalence of IFG tends to plateau in
middle age, whereas prevalence of IGT rises in old age, (iv) because
IGT is more common than IFG in most populations, it is more sen-
sitive (but slightly less speciﬁc) for identifying people who will de-
velop diabetes, (v) both IFG and IGT are associated with
cardiovascular disease risk factors including hypertension, dyslipi-
demia and other features of the metabolic syndrome, and ﬁnally
(vi) in unadjusted analysis, both IFG and IGT are associated with
cardiovascular disease and total mortality.
2.2. Vascular complications of pre-diabetes and diabetes
Pre-diabetes has been associated with microvascular [15,19]
and macrovascular complications [15,20,21]. Several studies have
demonstrated that IGT is associated with an increased risk of car-
diovascular mortality [22–24]. Once pre-diabetes progresses to
overt diabetes, the risk of cardiovascular disease greatly increases
[10,25,26]. It has also been demonstrated that HbA1c levels are
continuously and positively associated with cardiovascular and to-
tal mortality independent of other risk factors (27–30). In the EPIC
study [27], an increase in HbA1c of 1% points was associated with a
relative risk of death from any cause of 1.24 (95% CI, 1.14–1.34).
Danaei et al. [28] in a global study to assess the relationship ofmortality from ischemic heart study and glucose concentration,
concluded that higher than optimum blood glucose is a leading
cause of cardiovascular mortality in most world regions. Finally,
in the studies of Saydah et al. [29], based on the NHANES data,
and that of Dale et al. [30], based on a 20 years follow up of newly
diagnosed diabetes patients demonstrated that poor long term gly-
cemic control as indicated by increased HbA1c levels is associated
with higher cardiovascular and all cause mortality.
In recent years, the controversy, whether the control of hyper-
glycemia is beneﬁcial to reduce cardiovascular complication risk
has been settled. The Diabetes Control and Complications Trial
(DCCT) in type 1 [31] and UK prospective diabetes study [32] in
type 2 diabetes demonstrated that control of hyperglycemia re-
duces the risk of microvascular complications of diabetes. In the
UKPDS study, there was a 16% reduction in the risk of myocardial
infarction, but this difference was not statistically signiﬁcant.
However, there was a correlation between the risk of MI and
HbA1c level [33]. In a recent follow up of the UKPDS, it was dem-
onstrated that despite an early loss of glycemic differences, a con-
tinued reduction in microvascular risk and emergent risk
reductions for myocardial infarction or death from any cause were
observed during 10 years of post trial follow up [34]. Based on
studies like these [31,34] and the observations that HbA1c levels
are continuously and positively associated with cardiovascular
disease and total mortality independent of other cardiovascular
risk factors [27–30], the American Diabetes Association (ADA) rec-
ommended that a HbA1c <7% for microvascular disease preven-
tion, and the general goal of <7% appeared reasonable for many
adults for macrovascular risk reduction. In selected individuals,
a HbA1c goal lower than <7% might be reasonable if this can be
achieved without signiﬁcant hypoglycemia or other adverse ef-
fects of treatment [35]. This leads to the concept that perhaps
the lower the HbA1c, the better it was [36]. However, the results
of the recent studies, Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) [37] and Action in Diabetes and Vascular Disease
(ADVANCE) study [38] have led to re-examination of the ‘‘lower is
better” role of hyperglycemia in cardiovascular disease. Neither of
these two studies showed any beneﬁt of lowering the HbA1c to
6.4% and 6.3%, respectively; compared with the standard interven-
tion, which achieved a HbA1c level of 7.5% and 7.0%, respectively.
Moreover, in the ACCORD study, intensive therapy was associated
with increased mortality [37].
Thus, although it is not clear what the ‘ideal’ target for HbA1c
should be, it is apparent from the above discussion that many cases
of pre-diabetes and diabetes remain undiagnosed, pre-diabetes in-
creases the risk of progression to overt diabetes, and both pre-dia-
betes and diabetes are associated with an increased risk of
cardiovascular disease morbidity and mortality.3. Screening for diabetes
Effective treatments are now available to retard the progression
of pre-diabetes to diabetes [7,16] and to reduce the cardiovascular
risk in diabetes mellitus [31–34,39]. It, therefore, appears reason-
able to undertake aggressive screening for pre-diabetes and diabe-
tes to reduce the overall disease burden. However, whether to
screen for diabetes or not, and how to screen, remains controver-
sial. The ADA recommends screening for all adults who are over-
weight and have one of the following additional risk factors:
physical inactivity, ﬁrst degree relative with diabetes, members
of high risk ethnic populations, women who have delivered a baby
weighing more than 4.1 kg or were diagnosed as having gestational
diabetes mellitus, hypertension, HDL – cholesterol level <35 mg/dl
or triglyceride level >250 mg/dl, women with polycystic ovarian
syndrome, IGT or IFT on previous testing, other clinical conditions
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disease [35]. In the absence of above criteria, testing for diabetes
and pre-diabetes should begin at age 45 years. If results for diabe-
tes and pre-diabetes are normal, testing should be repeated at least
at 3 years intervals with consideration of more frequent testing
depending on initial results and risk status [35]. The US Preventive
Services Task Force (USPTF) recently updated its guidelines for
screening adults for type 2 diabetes mellitus [40]. This report
was based on a literature review of existing data in both MEDLINE
and Cochrane Library database. Based on their review the USPTF
concluded that screening for diabetes in asymptomatic individuals
with hypertension (blood pressure P135/80) was indicated. On
the other hand, the National Screening Committee (NSC) of UK,
after an extensive literature review, concluded that the case for
screening for undiagnosed diabetes is probably somewhat stronger
than it was at the time of their last review [41]. They also noted
that there is a good case for screening for IGT with the aim of pre-
venting some future diabetes and reducing cardiovascular disease.
An interesting discussion about whether to screen for diabetes or
not has been recently published in the Mayo Clinic Proceedings
[42–44].
In the aforementioned discussion, we agreed [44] with the
broader screening recommendations of the ADA [35] and Sheehy
et al. [42] in supporting more aggressive screening for diabetes,
as compared to the USPSTF more restrictive recommendations
[40]. Assuming that one is going to undertake screening, the opti-
mal methods for screening are also somewhat controversial. The
ADA recommends using FPG and OGTT and presently these are
used widely [35]. Both of these tests require measurement of plas-
ma glucose and also require at least an overnight fast. However,
the sensitivity of FPG is not very high and fails to detect 30–50%
of individuals with diabetes [45,46]. OGTT is inconvenient, costly,
time consuming, labor intensive, and has low reproducibility that
can add to confusion and uncertainty to conﬁrmation of the diag-
nosis of diabetes [45,46]. We have suggested in the past that
HbA1c may be a reasonable alternative for screening for diabetes
[47], possibly including GDM [48]. In recent years, there has been
an increasing support for the use of HbA1c for screening purposes
[45,46].
Bennett et al. [46], in a systemic review, concluded that HbA1c
and FPG are equally effective screening tools for the detection of
type 2 diabetes. In a study by McCane et al. [49] it was reported
that FPG, OGTT and HbA1c all three signiﬁcantly predicted the
development of retinopathy and nephropathy [49]. A recent con-
sensus statement published by a panel of experts in the area of
diagnosis, monitoring and management of diabetes, led by Saudek
et al. [50], recommended that: (1) screening standards should be
established that prompt further testing and closer follow up
including FPG 100 mg/dl or greater, random plasma glucose of
130 mg/dl or greater or HbA1c greater than 6.0%, (2) HbA1c 6.5–
6.9% or greater, conﬁrmed by a speciﬁc test (FPG or OGTT) should
establish the diagnosis of diabetes, (3) HbA1c of 7% or greater con-
ﬁrmed by another HbA1c or a speciﬁc test (FPG or OGTT) should
establish the diagnosis of diabetes. Although so far, ADA has not
endorsed using HbA1c as a diagnostic test, with the consensus of
several leading diabetes organizations, ADA’s Expert Committee
on the Diagnosis and Classiﬁcation of Diabetes plans to publish
guidelines recommending the HbA1c test as a diagnostic tool for
type 2 diabetes [51]. The reasons given for this change are that
both FPG and OGTT show thresholds for the diabetes speciﬁc com-
plications of retinopathy; the variability of glucose measures is
actually much larger than that of standardized A1c measurements.
While to date there are no criteria for using HbA1c in diagnosing
diabetes, A1c has a threshold for retinopathy, can be measured
anytime of day without regard to meal status and has less variabil-
ity [51].Although it appears that the community of diabetes experts
may be close to an agreement about the use of HbA1c for the
screening or diagnosis of diabetes, the issue of using HbA1c for
similar purposes is more controversial in gestational diabetes mel-
litus (GDM). Currently, the ADA recommends screening for GDM
using risk factor analysis and if appropriate, use of OGTT. A two-
step approach, using an initial screening by measuring plasma or
serum glucose 1 h after 50 gm oral glucose load and performing
diagnostic 100 gm glucose load on a separate day in women who
exceed the chosen threshold on 50 gm screening, is recommended
[35]. All the disadvantages of using an oral glucose load mentioned
above apply even more strongly to pregnant women who already
may have reduced tolerance to foods and drinks. Moreover, the
glucose load used is even greater [100 gm] compared to the glu-
cose load used in nonpregnant state (75 gm). Anecdotally, the
drink has been described as nauseating or even obnoxious by pa-
tients, and up to 4% women have reported vomiting following
ingestion of oral glucose load [52].
There are, however, few studies supporting the diagnostic util-
ity of HbA1c in GDM. This may be a result of the fact that most of
the studies were done in the 1980’s [53–57] when HbA1c assays
were diverse, and the test was not standardized [47]. Furthermore,
these studies were small and the diagnostic criteria used in these
studies were not uniform. Thus the conclusions drawn from these
studies were not clear.
The results of two recent larger studies from UAE addressing
HbA1c in GDM screening and diagnosis are also conﬂicting regard-
ing the sensitivity and speciﬁcity of the test [58,59]. Interestingly
both of these studies were performed by the same group. In their
earlier study [58], Agarwal et al. observed that HbA1c may have
potential as a screening test for GDM but they were not able to
conﬁrm that in the subsequent study [59]. In a retrospective study
in a Saudi population of 145 women in the third trimester of preg-
nancy, we observed that the sensitivity of HbA1c in predicting
GDM was 87%. The study design did not allow us to calculate spec-
iﬁcity [48]. In a recent review by the New Zealand GDM Technical
Working Party, this group recommended HbAlc as a practical ini-
tial screening test but noted that further research was needed
[60]. It is, therefore, apparent that further studies are needed to
determine the role of HbA1c in screening and diagnosis of GDM.4. Conclusion
The prevalence of diabetes continues to increase on a world
wide basis. A substantial proportion of subjects with pre-diabetes
and diabetes remain undiagnosed. Pre-diabetes progresses to overt
diabetes at the rate of approximately 5% unless appropriate inter-
ventions are introduced. Both pre-diabetes, and diabetes are asso-
ciated with an increased risk of cardiovascular complications.
Effective modalities to prevent the progression of pre-diabetes to
diabetes and to reduce the CV risk of diabetes are now available.
Therefore, we believe that aggressive screening of diabetes should
be undertaken. However, this issue remains controversial.
Although FPG and OGTT are widely used for screening, there is in-
creased recognition of the role of HbA1c for screening purposes. It
appears that we will be using HbA1c, not only for monitoring the
glycemic control of diabetes, but also for recognition of diabetes
in the near future. However, the role of HbA1c in screening for
GDM remains uncertain, and further studies are needed to clarify
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